Report Overview
The global contract research organization (CRO) service market is set to reach USD 186.317 billion in 2031, growing at a CAGR of 7.22% from a valuation of USD 131.459 billion in 2026.
The market for global contract research organisation (CRO) services is critical to providing outsourced research and development (R&D) solutions for the pharmaceutical, biopharmaceutical, and medical device industries. CRO's specialised service offerings, such as preclinical studies, clinical trial activities, laboratory testing, and regulatory consulting, allow the Pharmaceutical, Biopharmaceutical, and Medical Device industries to develop new therapies faster and at a lower cost.
The main drivers of growth in the CRO services market are the increasing demand for new and innovative therapies, the biopharmaceutical industry's ongoing trend of outsourcing, and the need to create efficiencies in clinical development. By developing products to meet the diverse needs and capabilities of successful healthcare companies worldwide, CROs have continued to foster and drive innovation while reducing operational burdens on these companies.
Contract Research Organizations (CRO) Services Market Trends:
The Contract Research Organisation (CRO) Services market includes professional services provided by research organisations that focus on contract clinical trials and bioavailability and/or bioequivalence studies on behalf of sponsors involved in developing new drugs. In India, the Government of India’s Ministry of Health & Family Welfare amended the New Drugs & Clinical Trial Regulations via G.S.R. 581 (E) dated 19 September 2024, with an effective date of 1 April 2025.
It defined CROs and began a regulatory system for dictating how CROs will be registered and operated. Specifically, as per these amended regulations, only CROs that have received registration from the Central Licensing Authority (CLA) are permitted to conduct clinical trials or other studies involving human subjects.
To help CROs comply with this new rule, the Central Drugs Standard Control Organisation, a part of the Government of India, has employed an online registry through the SUGAM portal. Effective 1 April 2025, it will be required that all CROs process their applications for CRO Registration on the SUGAM portal and submit the required documentation, as well as the appropriate fee, before beginning regulated research activities.
These regulatory changes create a consistent baseline for CRO Services in India. This will allow CROs nationwide to maintain consistency in meeting standardised compliance, oversight, and ethical best practices in their role as part of the National Clinical Research Framework.
Growth of the global drug discovery outsourcing market from USD 3.8 billion in 2022 to an expected USD 6.2 billion by 2031 reflects rising demand for discovery chemical services in pharmaceutical R&D. Surging demand for discovery chemical services feeds directly into the Contract Research Organisation Services market because drug developers are increasingly outsourcing early-stage research work to specialised providers.
As pharmaceutical companies focus internal resources on later-stage development, they rely on CROs for chemistry, biological screening, and lead optimisation expertise, expanding service volumes and revenues across the CRO ecosystem.
Contract Research Organizations (CRO) Services Market Drivers:
Rise in the global cases of chronic diseases and demand for new therapies: A global increase in chronic and non-communicable diseases such as cardiovascular disease, cancer, diabetes, and chronic respiratory disorders poses long-term healthcare challenges. Pharmaceutical and biopharmaceutical companies are expanding pipelines to include new therapeutic classes, personalised medicine, and combination therapies, increasing the demand for clinical trials and specialised testing supported by CROs.
Growing Investment in Research and Development: Increased investment in research and advanced technologies such as artificial intelligence and data analytics is driving CRO market growth. For instance, in November 2024, AstraZeneca announced an investment of approximately USD 3.5 billion for research and development and manufacturing of new drugs in the United States.
Contract Research Organizations (CRO) Services Market Segment Analysis:
By Molecule Type: Cell Gene Therapy
By molecule type, the Contract Research Organizations (CRO) Services Market is segmented into vaccines, cell gene therapy, and others. The cell gene therapy segment is expected to witness strong demand driven by the rise in chronic and rare genetic diseases, including cancer, cardiovascular disease, genetic disorders, and autoimmune diseases.
Cell and gene therapies involve modification of patient cells and require extensive clinical trial support, regulatory compliance, data management, and patient recruitment. As a result, biopharmaceutical companies increasingly partner with CROs to support these complex development programs.
By End-User: Pharmaceutical and Biopharmaceutical Companies
Pharmaceutical and biopharmaceutical companies represent a dominant end-user segment, driven by significant investment in biologics and therapies targeting life-threatening and rare diseases. Growth in the global clinical trial pipeline and increasing regulatory complexity continue to reinforce reliance on CRO services.
Contract Research Organizations (CRO) Services Market Geographical Outlook:
North America: United States
The pharmaceutical sector in the United States is experiencing a shift toward patient-centric drug development, supported by evolving regulatory guidance from the Food and Drug Administration (FDA). Continued approvals of novel drugs and increased R&D investment are driving demand for specialized CRO expertise.
Strategic collaborations, acquisitions, and government funding through agencies such as the National Institutes of Health further shape the CRO market landscape. However, ongoing tariff pressures and regulatory complexity may introduce operational challenges for CRO service providers.
Contract Research Organizations (CRO) Services Market Developments:
April 2026: Parexel acquired Vitrana to enhance AI-driven patient safety and pharmacovigilance solutions, improving automation, compliance, and operational efficiency in clinical development services.
February 2026: Worldwide Clinical Trials completed the acquisition of Catalyst Clinical Research, expanding oncology, biometrics, and functional service provider capabilities while strengthening global clinical trial technology and operational reach.
January 2026: WEP Clinical acquired Siron Clinical to expand Phase I–IV clinical trial delivery capabilities and strengthen European operations across rare disease and specialized therapeutic research services.
July 2025: Medpace raised its full-year revenue guidance following stronger clinical trial demand, reduced cancellations, and improved biotech funding conditions supporting CRO service market recovery.
August 2025: IQVIA and Veeva Systems announced long-term global clinical and commercial partnerships integrating software, data, and CRO service platforms for streamlined clinical development operations.
Contract Research Organizations (CRO) Services Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 131.459 billion |
| Total Market Size in 2031 | USD 186.317 billion |
| Forecast Unit | Billion |
| Growth Rate | 7.22% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Molecule Type, Type, Therapeutic Area, End-User |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Contract Research Organizations (CRO) Services Market Segmentation
By Molecule Type
Vaccines
Cell Gene Therapy
Others
By Type
Early Phase Development Services
Clinical Research Services
Laboratory Services
Consulting Services
By Therapeutic Area
Oncology
CNS Disorders
Other Therapeutic Areas
By End-User
Pharmaceuticals and Biopharmaceuticals Companies
Medical Devices Companies
Academic Institutes
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Others
Market Segmentation
By Molecule Type (2021-2031)
By Type (2021-2031)
By Therapeutic Area (2021-2031)
By End User (2021-2031)
By Geography (2021-2031)
Table of Contents
1. Executive Summary
2. Market Snapshot
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. Business Landscape
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. Technological Outlook
5. Contract Research Organizations (CRO) Services Market By Molecule Type (2021-2031)
5.1. Introduction
5.2. Vaccines
5.3. Cell Gene Therapy
5.4. Others
6. Contract Research Organizations (CRO) Services Market By Type (2021-2031)
6.1. Introduction
6.2. Early Phase Development Services
6.2.1. Preclinical
6.2.2. Toxicology Testing
6.2.3. Discovery Studies
6.2.4. Chemistry, Manufacturing, and Controls
6.2.5. Pharmacokinetics /Pharmacodynamics
6.3. Clinical Research Services
6.3.1. Phase I
6.3.2. Phase II
6.3.3. Phase III
6.3.4. Phase IV
6.3.5. Phase V
6.4. Laboratory Services
6.4.1. Analytical Testing
6.4.2. Bioanalytical Testing
6.4.3. Physical Characterization
6.4.4. Stability Testing, Batch Release Testing
6.4.5. Raw Material Testing
6.4.6. Other Analytical Testing
6.5. Consulting Services
7. Contract Research Organizations (CRO) Services Market By Therapeutic Area (2021-2031)
7.1. Introduction
7.2. Oncology
7.2.1. Breast Cancer
7.2.2. Lung Cancer
7.2.3. Colorectal Cancer
7.2.4. Prostate Cancer
7.2.5. Others
7.3. CNS Disorders
7.3.1. Infectious Diseases
7.3.2. Cardiovascular Diseases
7.3.3. Respiratory Disorders
7.3.4. Diabetes
7.4. Other Therapeutic Areas
8. Contract Research Organizations (CRO) Services Market By End User (2021-2031)
8.1. Introduction
8.2. Pharmaceuticals and Biopharmaceuticals Companies
8.3. Medical Devices Companies
8.4. Academic Institutes
9. Contract Research Organizations (CRO) Services Market By Geography (2021-2031)
9.1. Introduction
9.2. North America
9.2.1. By Molecule Type
9.2.2. By Type
9.2.3. By Therapeutic Area
9.2.4. By End-User
9.2.5. By Country
9.2.5.1. United States
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. By Molecule Type
9.3.2. By Type
9.3.3. By Therapeutic Area
9.3.4. By End-User
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. By Molecule Type
9.4.2. By Type
9.4.3. By Therapeutic Area
9.4.4. By End-User
9.4.5. By Country
9.4.5.1. United Kingdom
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Spain
9.4.5.5. Others
9.5. Middle East and Africa
9.5.1. By Molecule Type
9.5.2. By Type
9.5.3. By Therapeutic Area
9.5.4. By End-User
9.5.5. By Country
9.5.5.1. Saudi Arabia
9.5.5.2. UAE
9.5.5.3. Israel
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. By Molecule Type
9.6.2. By Type
9.6.3. By Therapeutic Area
9.6.4. By End-User
9.6.5. By Country
9.6.5.1. Japan
9.6.5.2. China
9.6.5.3. India
9.6.5.4. South Korea
9.6.5.5. Indonesia
9.6.5.6. Thailand
9.6.5.7. Taiwan
9.6.5.8. Others
10. Competitive Environment and Analysis
10.1. Major Players and Strategy Analysis
10.2. Market Share Analysis
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Competitive Dashboard
11. Company Profiles
11.1. Thermo Fisher Scientific Inc.
11.2. IQVIA Holdings Inc.
11.3. ICON plc
11.4. Parexel International Corporation
11.5. NAMSA
11.6. Labcorp Holdings Inc.
11.7. WuXi AppTec Co., Ltd.
11.8. Syneos Health, Inc.
11.9. Evotec SE
11.10. Novotech Health Holdings Pte. Ltd.
11.11. CliniExperts Inc.
11.12. PharPoint Research, Inc.
11.13. Veranex
12. Research Methodology
List of Figures
List of Tables
Contract Research Organizations (CRO) Services Market Report
Trusted by the world's leading organizations
